Clinical trial
Efficacy and Safety of Percutaneous Superselective Adrenal Arterial Embolization in the Treatment of Primary Aldosteronism With Bilateral Idiopathic Hyperaldosteronism: A Prospective Cohort Study
NCT05186675 is registered in ClinicalTrials.gov with Second Affiliated Hospital of Nanchang University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy and Safety of Percutaneous Superselective Adrenal Arterial Embolization in the Treatment of Primary Aldosteronism With Bilateral Idiopathic Hyperaldosteronism: A Prospective Cohort Study
- Lead sponsor
- Second Affiliated Hospital of Nanchang University
- Phase
- Not applicable
- Overall status
- Unknown status
- Start date
- January 1, 2022
- Completion date
- December 31, 2022
- Enrollment
- 50 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
primary aldosteronism due to adrenal hyperplasia (bilateral)